التخطي إلى المحتوى الرئيسي
العودة إلى المدونة
انقطاع الطمث وما حوله

Does hormone therapy cause weight gain? What the research says

L
Lunarahealth
7 7 دقائق قراءة
Verschillende doordrukstrips met tabletten en capsules op een lichtblauwe ondergrond.
الصورة: Christine Sandu عبر Unsplash

No. Hormone therapy does not make you gain weight. In a Cochrane review of 22 randomised trials, the difference against women taking nothing was +0.66 kg, and it was not significant (PMID 10796730). With a progestogen added, it was -0.47 kg. Also not significant.

Yet this fear makes many women turn down a treatment that could ease their symptoms. The fear is understandable. It is simply not true.

Here is what the research says, including what we do not know.

The short answer: no extra weight gain

The best synthesis of randomised trials found no weight difference between women on hormone therapy and women on nothing. Not for oestrogen alone, and not for oestrogen with a progestogen. The reviewers put it plainly: these regimens do not cause extra weight gain in addition to that normally gained at menopause (PMID 10796730).

Notice that last clause. Something does arrive in this phase of life. It just does not arrive because of the tablets, the gel or the patch.

What the 22 trials actually found

In these trials, women were randomly given hormone therapy or not. That is the only design that can separate cause from coincidence. The weight differences stayed small and were statistically indistinguishable from zero. BMI did not measurably change either.

Here are the numbers, alongside the newer evidence from a second analysis.

What was comparedResultStudy
Oestrogen alone vs no HRT.+0.66 kg (95% CI -0.62 to +1.93). Not significant.Cochrane, 22 randomised trials (PMID 10796730).
Oestrogen plus progestogen vs no HRT.-0.47 kg (95% CI -1.63 to +0.69). Not significant.Cochrane, 22 randomised trials (PMID 10796730).
BMI on combined therapy.-0.50 (95% CI -1.06 to +0.06). Not significant.Cochrane, 22 randomised trials (PMID 10796730).
Abdominal fat in women without diabetes.-6.8% (95% CI -11.8 to -1.9).Salpeter, 107 randomised trials (PMID 16918589).
HOMA-IR, a measure of insulin resistance.-12.9%.Salpeter, 107 randomised trials (PMID 16918589).
New-onset diabetes.RR 0.7 (95% CI 0.6 to 0.9). Less common.Salpeter, 107 randomised trials (PMID 16918589).

For oestrogen alone, the interval runs from almost a kilo lost to almost two kilos gained. That means we see no effect. No effect is not the same as a hidden effect.

The honest caveat about this evidence

That Cochrane review is from 2000. Its literature search stopped in 1998. It is old, and you should hear that from us rather than find it out yourself.

Cochrane has never updated it. It remains the highest level of evidence on this exact question. But old evidence deserves a second source beside it.

That second source exists, and it is bigger.

The newer evidence points the other way

A later analysis pooled 107 randomised trials. In women without diabetes, hormone therapy cut abdominal fat by 6.8% and HOMA-IR by 12.9%. New-onset diabetes became less common (RR 0.7). In women with diabetes, HOMA-IR fell by 35.8% (PMID 16918589).

Read that again. The pooled evidence does not point towards more fat. If anything, it points towards slightly less fat around the middle.

That is the exact opposite of the fear.

What it does not mean: that hormone therapy is a weight-loss drug. That claim appears nowhere in this research, and we are not going to make it here.

Why the fear still feels so real

Because the changes and the prescription arrive at the same time. Weight climbs gradually through midlife, with or without hormone therapy (PMID 30843880). And in exactly those years, your fat moves to your middle.

The figures: visceral fat rises by 6.24% a year and belly fat by 5.54% a year during the transition (PMID 34061966). Your trousers tighten while the scale barely moves.

Now put a box of tablets next to that. The conclusion suggests itself, and it is wrong.

It is a coincidence of timing, not cause and effect.

Large studies of women across the transition show that split neatly: weight follows chronological age, while the distribution of your fat follows the menopause (PMID 27417630). What oestrogen does and does not do here is covered in hormones and weight loss.

Fluid and breast tenderness are not fat

In the first few weeks, many women notice fluid retention and tender breasts. That is a well-known side effect and it is real. It is simply not fat tissue. It is water, and in most women it settles within a few weeks.

Yet this is often exactly what you register. The scale jumps a kilo and a half. Your ring feels tight. That feels like gaining weight.

If it persists, raise it with your doctor. A different dose or a different progestogen sometimes helps. Stopping straight away is rarely necessary.

What hormone therapy is actually for

HRT is a treatment for symptoms, not for your weight. It is meant for hot flushes, night sweats and genitourinary symptoms. The Dutch GP guideline on menopause, the NHG-Standaard De overgang, sets out when a GP considers it, and Thuisarts.nl explains that decision in plain language.

So we do not flip the promise around. Anyone selling you hormone therapy as a slimming aid is selling you something other than a medicine.

What it can do: reduce the symptoms that break up your nights. Whether calmer nights then calm your appetite is plausible but not proven in this group of women. We wrote that honestly in menopause sleep problems and appetite.

How it works in practice, from first consultation to settling on a dose, is covered in hormone therapy during menopause.

What a blood test does and does not do here

A blood test cannot tell you whether HRT will make you gain weight. It cannot, and we are not going to sell you that. What it does show is what the redistribution of fat is doing to your health. Visceral fat rises around your final period and tracks with thickening of the carotid artery, independent of BMI (PMID 33651741).

That is where the value sits. Not in an explanation for the scale, but in a picture of your blood sugar, your cholesterol and your inflammation markers.

You follow that with a complete metabolic panel: once before you start, and again six months later. Then you know what is really changing instead of what you suspect.

The wider context of weight in this phase sits in our main article: weight loss in menopause, what works and what does not.

When this article is not for you

Weight loss is not a healthy goal for everyone. Do not follow this article if you have or have had an eating disorder, are pregnant or breastfeeding, are underweight, use insulin, or have had bariatric surgery. Speak to your GP first.

If thoughts about food or your body start to take over, talk to your GP or contact an eating disorder helpline. That is not weakness. That is sense.

What to do next

Book an appointment with your GP and bring three things.

  • Your symptoms, with how often they come and how much they cost you.
  • Your question about weight, worded exactly like that. You are owed an answer.
  • Your risk factors, such as breast cancer in the family or a previous blood clot.

Hormone therapy is a prescription medicine and the decision is a clinical one. You make it with your doctor, not with a blog and not with us.

Ask the question. The answer is better than you think.

Sources

  1. Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev. 2000. PMID 10796730.
  2. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538-554. PMID 16918589.
  3. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. PMID 30843880.
  4. Greendale GA, Han W, Finkelstein JS, et al. Changes in regional fat distribution and anthropometric measures across the menopause transition. J Clin Endocrinol Metab. 2021;106(9):2520-2534. PMID 34061966.
  5. Karvonen-Gutierrez C, Kim C. Association of mid-life changes in body size, body composition and obesity status with the menopausal transition. Healthcare (Basel). 2016;4(3):42. PMID 27417630.
  6. Samargandy S, Matthews KA, Brooks MM, et al. Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis. Menopause. 2021;28(6):626-633. PMID 33651741.
  7. NHG-Standaard De overgang and Thuisarts.nl. Information on menopause and hormone therapy. Available via thuisarts.nl.

Every Lunara blood test result includes a professional review by a BIG-registered doctor. Always discuss your results with your GP before making treatment decisions.

مشاركة WhatsApp
L

الكاتب

Lunarahealth

فحوصات ذات صلة

مقالات ذات صلة